Index removal puts Plexus stock in focus

Plexus (PLXS) has been removed from several Russell value and small cap indices. This change can lead to index fund rebalancing and may draw attention to how the stock is currently being valued.

Plexus has seen short term pressure around the index removals, with a 7 day share price return of down 8.37% and a 30 day share price return of down 5.81%. However, this sits against a 90 day share price return of 19.04%, a year to date share price return of 74.66% and a 1 year total shareholder return of 95.85%. This suggests momentum has been building over a longer period even as recent trading reflects shifting sentiment and portfolio rebalancing.

If the Plexus story has you thinking about where else strong performance trends might emerge, this is a useful moment to scan the market for 19 top founder-led companies

After Plexus was removed from several Russell indices, the stock now trades roughly 10% below the average analyst price target. The key question is whether this reflects a cautious market appropriately adjusting expectations, or a potential discount that further valuation analysis may challenge.

Most Popular Narrative: 9.3% Undervalued

The most followed Plexus narrative pegs fair value at $293.25, above the last close of $265.89, framing recent index-related weakness against a higher long term anchor.

The company's increasing success in winning programs in high-margin, complex sectors such as healthcare/life sciences, aerospace, and defense (including strong defense pipeline in Europe and record sector wins), is shifting the revenue mix toward segments with higher pricing power and more stable, long-term contracts, this should positively impact both revenue consistency and net margin expansion.

Curious what underpins that valuation gap for Plexus? The narrative leans heavily on multi year revenue compounding, firmer margins, and a future earnings multiple usually reserved for sector standouts. The mix of contract visibility, capital returns, and assumed discount rate does a lot of heavy lifting here.

Result: Fair Value of $293.25 (UNDERVALUED)

However, Plexus still faces meaningful risks, including customer concentration that could unsettle revenue if large programs slow, as well as sector cyclicality that may pressure margins and growth assumptions.

Another View on Plexus: Cash Flows Point a Different Way

While the dominant Plexus narrative leans on earnings forecasts and a $293.25 fair value, the SWS DCF model lands in a very different place, with an estimated future cash flow value of $64.56 per share versus the current $265.89 price. This points to Plexus as expensive rather than undervalued. When the gap is this wide, which framework do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Plexus for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Plexus carrying both clear upside arguments and flagged concerns, this is a good moment to review the data yourself quickly and weigh both sides through the 2 key rewards and 1 important warning sign.

Looking for more Plexus investment ideas?

If Plexus has sharpened your focus on opportunities, do not stop here. Use the Simply Wall St screener to surface other stocks that fit the kind of profile you want.

• Target potential value opportunities by scanning a curated set of companies that pass quality filters with the 44 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks with higher yields and resilient payout histories using the 9 dividend fortresses.
• Dial back risk while staying invested by focusing on companies assessed with lower risk profiles through the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.